SCHEMBL6948356

SCHEMBL6948356

O=C(OC(=O)c1ccccc1OC(=O)c1ccccc1)c1ccccc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 1/20 0.72
KMT2A Q03164 6/20 0.59
MAPT P10636 3/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
LMNA P02545 4/20 0.54
ALDH1A1 P00352 3/20 0.54
GAA P10253 2/20 0.54
HSD17B10 Q99714 4/20 0.53
KDM4E B2RXH2 2/20 0.53
CYP1A2 P05177 1/20 0.53
CYP2C9 P11712 1/20 0.53
ESR1 P03372 2/20 0.51
ESR2 Q92731 2/20 0.51
MEN1 O00255 1/20 0.51
JAK2 O60674 1/20 0.51
USP2 O75604 1/20 0.51
ALOX15 P16050 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
TOP1 P11387 1/20 0.51
HPGD P15428 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13828284 0.89 HSD17B10 (0.69) SLC6A3KMT2AMAPTSMN1; SMN2LMNA
SCHEMBL13827370 0.89 HSD17B10 (0.69) SLC6A3KMT2AMAPTSMN1; SMN2LMNA
SCHEMBL13827371 0.89 HSD17B10 (0.69) SLC6A3KMT2AMAPTSMN1; SMN2LMNA
SCHEMBL2337247 0.88 KDM4E (0.66) SLC6A3KMT2AMAPTSMN1; SMN2LMNA
SCHEMBL1914132 0.85 SLC6A3 (0.72) SLC6A3KMT2AMAPTSMN1; SMN2LMNA
SCHEMBL28263594 0.85 HSD17B10 (0.72) SLC6A3KMT2AMAPTSMN1; SMN2LMNA
SCHEMBL113040 0.85 SLC6A3 (0.71) SLC6A3KMT2AMAPTSMN1; SMN2LMNA
SCHEMBL30505635 0.85 SLC6A3 (0.71) SLC6A3KMT2AMAPTSMN1; SMN2LMNA
SCHEMBL1979275 0.85 SLC6A3 (0.71) SLC6A3KMT2AMAPTSMN1; SMN2LMNA
SCHEMBL28549086 0.85 SLC6A3 (0.57) SLC6A3KMT2AMAPTSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116490643-A System and method for carbon dioxide reactor control 十二益公司 2023-07-25 CN disclosed
EP-3104835-B1 PULVURENT EFFERVESCENT TOPICAL TREATMENT COMPOSITION RECKITT BENCKISER LLC (US) 2019-02-13 EP disclosed
US-9877484-B2 Pulvurent effervescent topical treatment composition RECKITT BENCKISER LLC (US) 2018-01-30 US disclosed
US-20170006874-A1 PULVURENT EFFERVESCENT TOPICAL TREATMENT COMPOSITION RECKITT BENCKISER LLC (US) 2017-01-12 US disclosed
EP-3104835-A1 PULVURENT EFFERVESCENT TOPICAL TREATMENT COMPOSITION Reckitt Benckiser LLC (US) 2016-12-21 EP disclosed
CN-103402486-B Two-part cosmetic product 莱雅公司 2016-11-23 CN disclosed
WO-2015121659-A1 PULVURENT EFFERVESCENT TOPICAL TREATMENT COMPOSITION RECKITT BENCKISER LLC (US) 2015-08-20 WO disclosed
CN-103402486-A Two-part cosmetic product OREAL 2013-11-20 CN disclosed
WO-2003106688-A1 GLUCOSYLTRANSFERASES WHICH CLUCOSYLATE SALICYLIC ACID THE UNIVERSITY OF YORK (GB) 2003-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170006874-A1 PULVURENT EFFERVESCENT TOPICAL TREATMENT COMPOSITION SOST, FPR2, SHH SLC6A3 4679/4885KMT2A 3873/4885MAPT 1882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.